GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Debt-to-EBITDA

Ultimovacs ASA (OSL:ULTI) Debt-to-EBITDA

: -0.02 (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ultimovacs ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr1.83 Mil. Ultimovacs ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was kr1.89 Mil. Ultimovacs ASA's annualized EBITDA for the quarter that ended in Dec. 2023 was kr-235.75 Mil. Ultimovacs ASA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ultimovacs ASA's Debt-to-EBITDA or its related term are showing as below:

OSL:ULTI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.06   Med: -0.03   Max: -0.01
Current: -0.02

During the past 9 years, the highest Debt-to-EBITDA Ratio of Ultimovacs ASA was -0.01. The lowest was -0.06. And the median was -0.03.

OSL:ULTI's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.355 vs OSL:ULTI: -0.02

Ultimovacs ASA Debt-to-EBITDA Historical Data

The historical data trend for Ultimovacs ASA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.03 -0.01 -0.03 -0.02

Ultimovacs ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.04 -0.03 -0.02 -0.02

Competitive Comparison

For the Biotechnology subindustry, Ultimovacs ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultimovacs ASA Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Debt-to-EBITDA falls into.



Ultimovacs ASA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ultimovacs ASA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.827 + 1.886) / -212.965
=-0.02

Ultimovacs ASA's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.827 + 1.886) / -235.752
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Ultimovacs ASA  (OSL:ULTI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ultimovacs ASA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (OSL:ULTI) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (OSL:ULTI) Headlines

No Headlines